The evolving role of adiponectin as an additive biomarker in HFrEF.
- Resource Type
- Academic Journal
- Authors
- Sente T; Laboratory for Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium. tahnee.sente@uantwerpen.be.; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium. tahnee.sente@uantwerpen.be.; Gevaert A; Laboratory for Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.; Van Berendoncks A; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.; Vrints CJ; Laboratory for Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.; Hoymans VY; Laboratory for Cellular and Molecular Cardiology, Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.; Cardiovascular Diseases, Department of Translational Pathophysiological Research, University of Antwerp, Universiteitsplein 1, 2610, Antwerp, Belgium.
- Source
- Publisher: Kluwer Academic Publishers Country of Publication: United States NLM ID: 9612481 Publication Model: Print Cited Medium: Internet ISSN: 1573-7322 (Electronic) Linking ISSN: 13824147 NLM ISO Abbreviation: Heart Fail Rev Subsets: MEDLINE
- Subject
- Language
- English
Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF. The objective of this review is to provide an overview of current knowledge on the role of adiponectin in HF with reduced ejection fraction. We discuss the cardioprotective and (anti-) inflammatory actions of adiponectin and its potential use in clinical diagnosis and prognosis.